{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:41:34Z","timestamp":1788997294075,"version":"build-2803163510"},"reference-count":104,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic markers implicated in CP, their involvement in tumorigenic pathways, and their impact on CP prognosis and treatment. Methods: We undertook a focused review of relevant articles, clinical trials, and molecular summaries regarding CP. Results: Genetic and immunological markers show variable expression in different types of CP. BRAF is implicated in tumorigenesis in papillary CP (pCP), whereas CTNNB1 and EGFR are often overexpressed in adamantinomatous CP (aCP) and VEGF is overexpressed in aCP and recurrent CP. Targeted treatment modalities inhibiting these pathways can shrink or halt progression of CP. In addition, EGFR inhibitors may sensitize tumors to radiation therapy. These drugs show promise in medical management and neoadjuvant therapy for CP. Immunotherapy, including anti-interleukin-6 (IL-6) drugs and interferon treatment, are also effective in managing tumor growth. Ongoing clinical trials in CP are limited but are testing BRAF\/MET inhibitors and IL-6 monoclonal antibodies. Conclusions: Genetic and immunological markers show variable expression in different subtypes of CP. Several current molecular treatments have shown some success in the management of this disease. Additional clinical trials and targeted therapies will be important to improve CP patient outcomes.<\/jats:p>","DOI":"10.31083\/j.fbl2704136","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:53:52Z","timestamp":1650588832000},"source":"Crossref","is-referenced-by-count":15,"title":["Targeted Therapy in the Management of Modern Craniopharyngiomas"],"prefix":"10.31083","volume":"27","author":[{"given":"Maikerly","family":"Reyes","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Taghvaei","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Sathe","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Collopy","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giyarpuram N.","family":"Prashant","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Evans","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karsy","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University of Utah, Salt Lake City, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, et al. International Society of Neuropathology\u2013Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathology. 2014; 24: 429\u2013435.","DOI":"10.1111\/bpa.12171"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Karavitaki N, Cudlip S, Adams CBT, Wass JAH. Craniopharyngiomas. Endocrine Reviews. 2006; 27: 371\u2013397.","DOI":"10.1210\/er.2006-0002"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Larkin S, Karavitaki N. Recent advances in molecular pathology of craniopharyngioma. F1000Research. 2017; 6: 1202.","DOI":"10.12688\/f1000research.11549.1"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Van Effenterre R, Boch AL. Craniopharyngiomas. Annales d\u2019Endocrinologie. 2007; 68: 412\u2013421.","DOI":"10.1016\/j.ando.2007.08.001"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"M\u00fcller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera J, Puget S. Craniopharyngioma. Nature Reviews Disease Primers. 2019; 5: 75.","DOI":"10.1038\/s41572-019-0125-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Stamm AC, Vellutini E, Balsalobre L. Craniopharyngioma. Otolaryngologic Clinics of North America. 2011; 44: 937\u201352, viii.","DOI":"10.1016\/j.otc.2011.06.015"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"M\u00fcller HL. Craniopharyngioma. Endocrine Reviews. 2014; 35: 513\u2013543.","DOI":"10.1210\/er.2013-1115"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Boch AL, van Effenterre R, Kujas M. Craniopharyngiomas in two consanguineous siblings: case report. Neurosurgery. 1997; 41: 1185\u20131187.","DOI":"10.1097\/00006123-199711000-00031"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Alexandraki KI, Kaltsas GA, Karavitaki N, Grossman AB. The Medical Therapy of Craniopharyngiomas: the Way Ahead. the Journal of Clinical Endocrinology & Metabolism. 2019; 104: 5751\u20135764.","DOI":"10.1210\/jc.2019-01299"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. The Lancet. 2001; 357: 425\u2013431.","DOI":"10.1016\/S0140-6736(00)04006-X"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Pereira AM, Schmid EM, Schutte PJ, Voormolen JHC, Biermasz NR, van Thiel SW, et al. High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clinical Endocrinology. 2005; 62: 197\u2013204.","DOI":"10.1111\/j.1365-2265.2004.02196.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lamas Oliveira C. Metabolic consequences of craniopharyingioma and their management. Endocrinologia y Nutricion. 2013; 60:529\u2013534.","DOI":"10.1016\/j.endoen.2012.11.010"},{"key":"ref13","unstructured":"Forbes JA, Ord\u00f3\u00f1ez-Rubiano EG, Tomasiewicz HC, Banu MA, Younus I, Dobri GA, et al. Endonasal endoscopic transsphenoidal resection of intrinsic third ventricular craniopharyngioma: surgical results. Journal of Neurosurgery. 2018; 1\u201311."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Conti A, Pontoriero A, Ghetti I, Senger C, Vajkoczy P, Pergolizzi S, et al. Benefits of image-guided stereotactic hypofractionated radiation therapy as adjuvant treatment of craniopharyngiomas. a review. Child\u2019s Nervous System. 2019; 35: 53\u201361.","DOI":"10.1007\/s00381-018-3954-z"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Albano L, Losa M, Flickinger J, Mortini P, Minniti G. Radiotherapy of Parasellar Tumours. Neuroendocrinology. 2020; 110: 848\u2013858.","DOI":"10.1159\/000506902"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Dandurand C, Sepehry AA, Asadi Lari MH, Akagami R, Gooderham P. Adult Craniopharyngioma: Case Series, Systematic Review, and Meta-Analysis. Neurosurgery. 2018; 83: 631\u2013641.","DOI":"10.1093\/neuros\/nyx570"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wang G, Zhang X, Feng M, Guo F. Comparing survival outcomes of gross total resection and subtotal resection with radiotherapy for craniopharyngioma: a meta-analysis. Journal of Surgical Research. 2018; 226: 131\u2013139.","DOI":"10.1016\/j.jss.2018.01.029"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Elliott RE, Hsieh K, Hochm T, Belitskaya-Levy I, Wisoff J, Wisoff JH. Efficacy and safety of radical resection of primary and recurrent craniopharyngiomas in 86 children. Journal of Neurosurgery. Pediatrics. 2010; 5: 30\u201348.","DOI":"10.3171\/2009.7.PEDS09215"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Asha MJ, Oswari S, Takami H, Velasquez C, Almeida JP, Gentili F. Craniopharyngiomas: Challenges and Controversies. World Neurosurgery. 2020; 142: 593\u2013600.","DOI":"10.1016\/j.wneu.2020.05.172"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Fouda MA, Scott RM, Marcus KJ, Ullrich N, Manley PE, Kieran MW, et al. Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. Child\u2019s Nervous System. 2020; 36: 291\u2013296.","DOI":"10.1007\/s00381-019-04294-x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Merchant TE, Kiehna EN, Sanford RA, Mulhern RK, Thompson SJ, Wilson MW, et al. Craniopharyngioma: the St. Jude Children\u2019s Research Hospital experience 1984\u20132001. International Journal of Radiation Oncology, Biology, Physics. 2002; 53: 533\u2013542.","DOI":"10.1016\/S0360-3016(02)02799-2"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Sadashivam S, Menon G, Abraham M, Nair SN. Adult craniopharyngioma: the role of extent of resection in tumor recurrence and long-term functional outcome. Clinical Neurology and Neurosurgery. 2020; 192: 105711.","DOI":"10.1016\/j.clineuro.2020.105711"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Larkin SJ, Ansorge O. Pathology and pathogenesis of craniopharyngiomas. Pituitary. 2013; 16: 9\u201317.","DOI":"10.1007\/s11102-012-0418-4"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Martinez-Barbera JP, Buslei R. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models. Journal of Pediatric Endocrinology & Metabolism. 2015; 28: 7\u201317.","DOI":"10.1515\/jpem-2014-0442"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Coury JR, Davis BN, Koumas CP, Manzano GS, Dehdashti AR. Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review. Neurosurgical Review. 2020; 43: 41\u201348.","DOI":"10.1007\/s10143-018-0978-5"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Szeifert GT, Sipos L, Horv\u00e1th M, Sarker MH, Major O, Salomv\u00e1ry B, et al. Pathological characteristics of surgically removed craniopharyngiomas: analysis of 131 cases. Acta Neurochirurgica. 1993; 124: 139\u2013143.","DOI":"10.1007\/BF01401137"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"H\u00f6lsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathologica Communications. 2016; 4: 20.","DOI":"10.1186\/s40478-016-0287-6"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics. 2014; 46: 161\u2013165.","DOI":"10.1038\/ng.2868"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Rostami E, Witt Nystr\u00f6m P, Libard S, Wikstr\u00f6m J, Casar-Borota O, Gudjonsson O. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochirurgica. 2017; 159: 2217\u20132221.","DOI":"10.1007\/s00701-017-3311-0"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhang C, Pan J, Chen L, Qi S. Interleukin\u20116 induces an epithelial\u2011mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. Molecular Medicine Reports. 2017; 15: 4123\u20134131.","DOI":"10.3892\/mmr.2017.6538"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, et al. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. Journal of the National Cancer Institute. 2016; 108: djv310.","DOI":"10.1093\/jnci\/djv310"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Aylwin SJB, Bodi I, Beaney R. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary. 2016; 19: 544\u2013546.","DOI":"10.1007\/s11102-015-0663-4"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Roque A, Odia Y. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncology. 2017; 6: 95\u201399.","DOI":"10.2217\/cns-2016-0034"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Himes BT, Ruff MW, Van Gompel JJ, Park SS, Galanis E, Kaufmann TJ, et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. Journal of Neurosurgery. 2018; 130: 1299\u20131303.","DOI":"10.3171\/2017.11.JNS172373"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Bernstein A, Mrowczynski OD, Greene A, Ryan S, Chung C, Zacharia BE, et al. Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. Journal of Neurosurgery. 2019; 133: 1704\u20131709.","DOI":"10.3171\/2019.8.JNS19643"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Rao M, Bhattacharjee M, Shepard S, Hsu S. Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report. Oncotarget. 2019; 10: 6038\u20136042.","DOI":"10.18632\/oncotarget.27203"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Juratli TA, Jones PS, Wang N, Subramanian M, Aylwin SJB, Odia Y, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019; 125: 2910\u20132914.","DOI":"10.1002\/cncr.32197"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Khaddour K, Chicoine MR, Huang J, Dahiya S, Ansstas G. Successful Use of BRAFMEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma. Journal of the National Comprehensive Cancer Network. 2020; 18: 1590\u20131595.","DOI":"10.6004\/jnccn.2020.7624"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Di Stefano AL, Guyon D, Sejean K, Feuvret L, Villa C, Berzero G, et al. Medical debulking with BRAFMEK inhibitors in aggressive BRAF-mutant craniopharyngioma. Neuro-Oncology Advances. 2020; 2: vdaa141.","DOI":"10.1093\/noajnl\/vdaa141"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Chik CL, van Landeghem FKH, Easaw JC, Mehta V. Aggressive Childhood-onset Papillary Craniopharyngioma Managed with Vemurafenib, a BRAF Inhibitor. Journal of the Endocrine Society. 2021; 5: bvab043.","DOI":"10.1210\/jendso\/bvab043"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Yue Q, Yu Y, Shi Z, Wang Y, Zhu W, Du Z, et al. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. Journal of Neurosurgery. 2018; 129: 27\u201334.","DOI":"10.3171\/2017.4.JNS163113"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, et al. Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. American Journal of Pathology. 2002; 161: 1997\u20132001.","DOI":"10.1016\/S0002-9440(10)64477-X"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Boult JKR, Apps JR, H\u00f6lsken A, Hutchinson JC, Carreno G, Danielson LS, et al. Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. Brain Pathology. 2018; 28: 475\u2013483.","DOI":"10.1111\/bpa.12525"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Hengartner AC, Prince E, Vijmasi T, Hankinson TC. Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurgical Focus. 2020; 48: E7.","DOI":"10.3171\/2019.10.FOCUS19705"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. New England Journal of Medicine. 2009; 361: 1173\u20131178.","DOI":"10.1056\/NEJMoa0902903"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"H\u00f6lsken A, Kreutzer J, Hofmann BM, Hans V, Oppel F, Buchfelder M, et al. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas. Brain Pathology. 2009; 19: 357\u2013364.","DOI":"10.1111\/j.1750-3639.2008.00180.x"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Stache C, H\u00f6lsken A, Schlaffer S, Hess A, Metzler M, Frey B, et al. Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathology. 2015; 25: 1\u201310.","DOI":"10.1111\/bpa.12148"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Esheba GE, Hassan AA. Comparative immunohistochemical expression of beta-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas. Journal of the Egyptian National Cancer Institute. 2015; 27: 139\u201345.","DOI":"10.1016\/j.jnci.2015.06.003"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Adams JC. Roles of fascin in cell adhesion and motility. Current Opinion in Cell Biology. 2004; 16: 590\u2013596.","DOI":"10.1016\/j.ceb.2004.07.009"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPKERK pathway as a novel therapeutic target. Acta Neuropathologica. 2018; 135: 757\u2013777.","DOI":"10.1007\/s00401-018-1830-2"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"H\u00f6lsken A, Stache C, Schlaffer SM, Flitsch J, Fahlbusch R, Buchfelder M, et al. Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche? Pituitary. 2014; 17: 546\u2013556.","DOI":"10.1007\/s11102-013-0543-8"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Lee C, Hung H, Hung P, Shieh Y. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Molecular Cancer. 2010; 9: 64.","DOI":"10.1186\/1476-4598-9-64"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Stache C, Bils C, Fahlbusch R, Flitsch J, Buchfelder M, Stefanits H, et al. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin. Neurosurgical Focus. 2016; 41: E14.","DOI":"10.3171\/2016.9.FOCUS16316"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Gaston-Massuet C, Andoniadou CL, Signore M, Jayakody SA, Charolidi N, Kyeyune R, et al. Increased Wingless (Wnt) signaling in pituitary progenitor\/stem cells gives rise to pituitary tumors in mice and humans. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108: 11482\u201311487.","DOI":"10.1073\/pnas.1101553108"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Andoniadou CL, Matsushima D, Mousavy Gharavy SN, Signore M, Mackintosh AI, Schaeffer M, et al. Sox2(+) stem\/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. Cell Stem Cell. 2013; 13: 433\u2013445.","DOI":"10.1016\/j.stem.2013.07.004"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Pettorini BL, Frassanito P, Caldarelli M, Tamburrini G, Massimi L, Di Rocco C. Molecular pathogenesis of craniopharyngioma: switching from a surgical approach to a biological one. Neurosurgical Focus. 2010; 28: E1.","DOI":"10.3171\/2010.1.FOCUS09300"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Steinbok P, Hukin J. Intracystic treatments for craniopharyngioma. Neurosurgical Focus. 2010; 28: E13.","DOI":"10.3171\/2010.1.FOCUS09315"},{"key":"ref58","unstructured":"Shahzadi S, Soltani A, Shahzadi A, Parsa K. Treatment of Cystic Craniopharyngioma with Intracystic Stereotactic Instillation of Phosphorus 32. Iranian Journal of Child Neurology. 2017; 11: 31\u201336."},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Pettorini BL, Inzitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, et al. The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Child\u2019s Nervous System. 2010; 26: 1779\u20131784.","DOI":"10.1007\/s00381-010-1245-4"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Donson AM, Apps J, Griesinger AM, Amani V, Witt DA, Anderson RCE, et al. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. Journal of Neuropathology and Experimental Neurology. 2017; 76: 779\u2013788.","DOI":"10.1093\/jnen\/nlx061"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer. 2009; 9: 798\u2013809.","DOI":"10.1038\/nrc2734"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. Journal of Immunology. 1996; 157: 231\u2013238.","DOI":"10.4049\/jimmunol.157.1.231"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. Journal of Immunology. 1995; 155: 3112\u20133123.","DOI":"10.4049\/jimmunol.155.6.3112"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Andrysiak-Mamos E, Sagan K, Sagan L, Sowi\u0144ska-Przepiera E, Syrenicz A. Cystic lesions of the sellar-suprasellar region - diagnosis and treatment. Endokrynologia Polska. 2018; 69: 212\u2013228.","DOI":"10.5603\/EP.2018.0023"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Zhu J, You C. Craniopharyngioma: Survivin expression and ultrastructure. Oncology Letters. 2015; 9: 75\u201380.","DOI":"10.3892\/ol.2014.2690"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Tena-Suck ML, Ortiz-Plata A, Gal\u00e1n F, S\u00e1nchez A. Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Annals of Diagnostic Pathology. 2009; 13: 82\u201388.","DOI":"10.1016\/j.anndiagpath.2008.12.004"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ebrahimi A, Honegger J, Schluesener H, Schittenhelm J. Osteonectin expression in surrounding stroma of craniopharyngiomas: association with recurrence rate and brain infiltration. International Journal of Surgical Pathology. 2013; 21: 591\u2013598.","DOI":"10.1177\/1066896913486695"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Lubansu A, Ruchoux M, Brotchi J, Salmon I, Kiss R, Lefranc F. Cathepsin B, D and K expression in adamantinomatous craniopharyngiomas relates to their levels of differentiation as determined by the patterns of retinoic acid receptor expression. Histopathology. 2003; 43: 563\u2013572.","DOI":"10.1111\/j.1365-2559.2003.01751.x"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Gong J, Zhang H, Xing S, Li C, Ma Z, Jia G, et al. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children. Cancer Biomarkers. 2014; 14: 241\u2013251.","DOI":"10.3233\/CBM-140397"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Xu J, Zhang S, You C, Wang X, Zhou Q. Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surgical Neurology. 2006; 66: S30\u2013S34.","DOI":"10.1016\/j.surneu.2006.05.047"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Yu R, Melmed S. Pituitary tumor transforming gene: an update. Frontiers of Hormone Research. 2004; 32: 175\u2013185.","DOI":"10.1159\/000079044"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Alexandraki KI, Xekouki P. Medical Therapy for Craniopharyngiomas. European Endocrinology. 2021; 17: 121.","DOI":"10.17925\/EE.2021.17.2.121"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Coy S, Rashid R, Lin J, Du Z, Donson AM, Hankinson TC, et al. Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro-Oncology. 2018; 20: 1101\u20131112.","DOI":"10.1093\/neuonc\/noy035"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Lin D, Wang Y, Zhou Z, Lin Z. Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: a Study of the Differences and Clinical Significance. World Neurosurgery. 2019; 127: e212\u2013e220.","DOI":"10.1016\/j.wneu.2019.02.212"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018; 37: 3183\u20133199.","DOI":"10.1038\/s41388-018-0171-x"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Minor D, Ribas A, Lebbe C, O\u2019Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. Journal of Clinical Oncology. 2013; 31: 3205\u20133211.","DOI":"10.1200\/JCO.2013.49.8691"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Tsoukalas N, Tsapakidis K, Alexandraki KI. The role of palbociclib in thyroid carcinoma with BRAF mutation. Gland Surgery. 2018; 7: S82\u2013S85.","DOI":"10.21037\/gs.2018.03.07"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"H\u00f6lsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Bl\u00fcmcke I, Buslei R. EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clinical Cancer Research. 2011; 17: 4367\u20134377.","DOI":"10.1158\/1078-0432.CCR-10-2811"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Gump JM, Donson AM, Birks DK, Amani VM, Rao KK, Griesinger AM, et al. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathologica Communications. 2015; 3: 30.","DOI":"10.1186\/s40478-015-0211-5"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England Journal of Medicine. 2015; 372: 30\u201339.","DOI":"10.1056\/NEJMoa1412690"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. 2015; 386: 444\u2013451.","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Welsh SJ, Corrie PG. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Therapeutic Advances in Medical Oncology. 2015; 7: 122\u2013136.","DOI":"10.1177\/1758834014566428"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. The New England Journal of Medicine. 2017; 377: 1813\u20131823.","DOI":"10.1056\/NEJMoa1708539"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Hauschild A, Grob J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012; 380: 358\u2013365.","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Fujio S, Juratli TA, Arita K, Hirano H, Nagano Y, Takajo T, et al. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas. Neurosurgery. 2019; 85: 204\u2013210.","DOI":"10.1093\/neuros\/nyy569"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Herbst RS, Fukuoka M, Baselga J. Gefitinib\u2013a novel targeted approach to treating cancer. Nature Reviews. Cancer. 2004; 4: 956\u2013965.","DOI":"10.1038\/nrc1506"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Vidal S, Kovacs K, Lloyd RV, Meyer FB, Scheithauer BW. Angiogenesis in patients with craniopharyngiomas: correlation with treatment and outcome. Cancer. 2002; 94: 738\u2013745.","DOI":"10.1002\/cncr.10281"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Sun HI, Akgun E, Bicer A, Ozkan A, Bozkurt SU, Kurtkaya O, et al. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery. 2010; 66: 744\u201350; discussion 750.","DOI":"10.1227\/01.NEU.0000367553.65099.14"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Xia Z, Liu W, Li S, Jia G, Zhang Y, Li C, et al. Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma. Neurochemical Research. 2011; 36: 2346\u20132351.","DOI":"10.1007\/s11064-011-0560-9"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Xu J, You C, Liu H, Liu Z, Li J, Li Q. Relative quantitative expression of hypoxia-inducible factor 1 alpha messenger ribonucleic acid in recurrent craniopharyngiomas. Neurology India. 2014; 62: 53.","DOI":"10.4103\/0028-3886.128291"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Agozzino L, Ferraraccio F, Accardo M, Esposito S, Agozzino M, Cuccurullo L. Morphological and ultrastructural findings of prognostic impact in craniopharyngiomas. Ultrastructural Pathology. 2006; 30: 143\u2013150.","DOI":"10.1080\/01913120500408018"},{"key":"ref92","doi-asserted-by":"crossref","unstructured":"Hu C, Chen J, Meng Y, Zhang J, Wang Y, Liu R, et al. Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma. Medicine. 2018; 97: e11136.","DOI":"10.1097\/MD.0000000000011136"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Grob S, Mirsky DM, Donson AM, Dahl N, Foreman NK, Hoffman LM, et al. Targeting IL-6 is a Potential Treatment for Primary Cystic Craniopharyngioma. Frontiers in Oncology. 2019; 9: 791.","DOI":"10.3389\/fonc.2019.00791"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Whelan R, Prince E, Gilani A, Hankinson T. The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. Journal of Clinical Medicine. 2020; 9: 519.","DOI":"10.3390\/jcm9020519"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Sen GC, Lengyel P. The interferon system. a bird\u2019s eye view of its biochemistry. Journal of Biological Chemistry. 1992; 267: 5017\u20135020.","DOI":"10.1016\/S0021-9258(18)42719-6"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Hertzog PJ, Hwang SY, Kola I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Molecular Reproduction and Development. 1994; 39: 226\u2013232.","DOI":"10.1002\/mrd.1080390216"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Kilday J, Caldarelli M, Massimi L, Chen RH, Lee YY, Liang M, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro-Oncology. 2018; 19: 1398\u20131407.","DOI":"10.1093\/neuonc\/nox056"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Cavalheiro S, Di Rocco C, Valenzuela S, Dastoli PA, Tamburrini G, Massimi L, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurgical Focus. 2010; 28: E12.","DOI":"10.3171\/2010.1.FOCUS09310"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Ierardi DF, Fernandes MJS, Silva IR, Thomazini-Gouveia J, Silva NS, Dastoli P, et al. Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas. Child\u2019s Nervous System. 2008; 23: 1041\u20131046.","DOI":"10.1007\/s00381-007-0409-3"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Dastoli PA, Nic\u00e1cio JM, Silva NS, Capellano AM, Toledo SRC, Ierardi D, et al. Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon. Arquivos De Neuro-Psiquiatria. 2011; 69: 50\u201355.","DOI":"10.1590\/S0004-282X2011000100011"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Jakacki RI, Cohen BH, Jamison C, Mathews VP, Arenson E, Longee DC, et al. Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. Journal of Neurosurgery. 2000; 92: 255\u2013260.","DOI":"10.3171\/jns.2000.92.2.0255"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-alpha-2b for children with recurrent craniopharyngioma. Journal of Neurosurgery: Pediatrics. 2012; 10: 498\u2013503.","DOI":"10.3171\/2012.9.PEDS12225"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. The New England Journal of Medicine. 2000; 343: 1666\u20131672.","DOI":"10.1056\/NEJM200012073432301"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"Goldman S, Pollack IF, Jakacki RI, Billups CA, Poussaint TY, Adesina AM, et al. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro-Oncology. 2000; 22: 1696\u20131704.","DOI":"10.1093\/neuonc\/noaa119"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/4\/10.31083\/j.fbl2704136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:06:06Z","timestamp":1732709166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/4\/10.31083\/j.fbl2704136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00477-4"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2704136","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"article-number":"136"}}